VCAM1 and myeloid sarcoma: Natalizumab blocks the bindings of α4β1 integrin to vascular cell adhesion molecule 1 (VCAM-1) and α4β7 integrin to mucosal addressin cell adhesion molecule 1 (MadCAM-1) on endothelial cells in MS and CD [15,16].